학술논문
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Document Type
Article
Author
Chekerov, R.; Richter, R.; Braicu, E.I.; Sehouli, J.; Hilpert, F.; Mahner, S.; El-Balat, A.; Harter, P.; du Bois, A.; De Gregorio, N.; Fridrich, C.; Markmann, S.; Potenberg, J.; Lorenz, R.; Oskay-Oezcelik, G.; Schmidt, M.; Krabisch, P.; Lueck, H.-J.; Lichtenegger, W.; Yalcinkaya, I.; Kittner, M.; Konwert, E.; Keller, M.; Mustea, A.; Koensgen-Mustea, D.; Pietzner, K.; Camara, O.; Wimberger, P.; Elser, G.; Polleis, S.
Source
In: The Lancet Oncology . (The Lancet Oncology, September 2018, 19(9):1247-1258)
Subject
Language
English
ISSN
14745488
14702045
14702045